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Background: The non-responders rate to cardiac resynchronization therapy (CRT) may be due to incomplete 
resynchronization as dyssynchrony can persist in about 30% of patients. We hypothesized that CRT with triple site 
ventricular stimulation (TRIV) may improve resynchronization and its outcomes. 
 
Objective: We assessed the feasibility and safety of TRIV and collected data on clinical outcomes to dimension future 
studies. 
 
Methods: Our pilot randomized trial was designed to assess the safety and feasibility of TRIV with 2 right and 1 left 
ventricular leads as compared with conventional CRT. The primary endpoint was the rate of severe adverse events 
(SAE) at 6 months. Secondary endpoints included functional improvement parameters, quality of life (QOL) score, and 
changes of echocardiographic indices at 6 and at 12 months in a subset of patients. 
  
Results: 76 patients were enrolled at 11 centers and randomized to control or TRIV arm. All implant procedures were 
successful but one.  At 6 month, there was no statistical difference between proportions of patients with at least one SAE 
in both groups (34.1% vs. 25.7%, p=0.425). There was also no difference between functional improvement parameters, 
6-minutes walking distances (p= 0.40), QOL scores (p = 0.27) and echographic indices. At 12 months, proportion of 
patients with a LVEF gain of more than 5%, 10 %, 15 % was significantly superior with TRIV. 
 
Conclusion: TriV pacing is an effective and safe technique and may provide a greater benefit on ventricular remodeling 
than conventional CRT. Further studies are needed to assess its long term benefit (NCT00887237). 
 
Keywords: cardiac resynchronization therapy; multisite pacing; congestive heart failure 
 
Introduction 
Cardiac resynchronization therapy (CRT) is a recommended treatment for selected patients with symptomatic heart 
failure (HF). Although most treated patients show a benefit from CRT, a lack of response is observed for about 25-30% 
of them1 whatever the response criteria used either based on the clinical status (NYHA class, clinical composite score) 
or on ventricular remodeling parameters assessed by echography (Left ventricle end of systole volume). This rate has 
remained remarkably stable since the therapy started and has motivated many studies to better understand the 
underlying physiopathology and the CRT action mechanisms.  
 
Among the various research axes, increasing the number of pacing sites in an attempt to better homogenize the cardiac 
mechanical activity has been evaluated. A configuration with two RV leads and one LV lead was tested acutely in three 
studies2,3,4. In all cases, it demonstrated a significant improvement of cardiac performance whether assessed by 
echographic parameters or LV dP/dt measurements. First results with triple-site ventricular stimulation are encouraging 
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and this approach might become a treatment option for CRT candidates provided its feasibility, safety and efficacy is 
demonstrated at larger scale. In the present study, we focused on the safety of this pacing configuration and collected 
data on clinical outcomes to dimension future studies. 
 
Methods 
This was a pilot, multicenter, prospective, parallel, randomized, controlled trial conducted in 11 French centers. All 
patients were informed and granted their written informed consent as approved by ethics committee. Patients were 
enrolled in the study if they were candidate to a de novo CRT-P or CRT-D. Criteria for inclusion into the study included 
LV dysfunction due to either ischemic or non-ischemic cardiomyopathy with an LV ejection fraction (LVEF) < 35%, New 
York Heart Association (NYHA) class II, III or IV functional status, and optimal medical therapy. Patients had to be in 
sinus rhythm with QRS duration > 120 milliseconds for NYHA class III and IV patients and > 150 milliseconds for NYHA 
class II patients5,6. Patients with complete AV block were excluded. Enrolled patients were randomly assigned in a 1:1 
fashion to receive either a standard CRT system with a bipolar LV lead and a RV lead positioned at the RV apex 
(Control group) or a TRIV system (test group) with two RV leads: one positioned at the apex, the other in a high septal 
position, at the level of the His bundle or above. Randomization occurred in blocks within centers. The septal RV and the 
bipolar LV leads were connected to the LV port using parallel Y-adaptor (Medtronic model 2872). This configuration was 
chosen to avoid any oversensing on the RV channel. Patients were blinded for the allocated intervention. At pre-
discharge, patients underwent A-V delay optimization under echocardiographic guidance to maximize diastolic filling. VV 
delay was set to zero millisecond for all patients in both groups. Device programming was left to investigators discretion 
with the exception of the LV capture management feature that was left off. 
 
Data collection 
Patients underwent the following evaluations at baseline: NYHA functional class; 6-minute walking test; QOL evaluation 
using the Minnesota Living with Heart Failure Questionnaire (MLWHF); Echocardiography exam, which included 
measurement of LVEF, LV diastolic and systolic dimensions, end diastolic and systolic volumes (during all the study, 
echography exams were performed in a blinded fashion); and QRS width on 12-lead ECG. Duration of the procedure 
and acute electrical parameters values – pacing threshold and impedance, sensed signal amplitude – were collected. At 
each follow-up (FU) visit, pre-discharge and 6 months, the CRT system proper functioning was assessed. Threshold test 
in the TRIV group were performed using 12-lead ECG to better identify QRS morphology changes. Baseline variables 
were reevaluated three, and six months after randomization. Clinical composite score (CCS)7 was evaluated at 6 month 
FU. The echocardiography exam and electrical parameters measurements were repeated at 12 month for all patients 
included in Rouen. All adverse events (AE) were reported and adjudicated by an independent AE committee that 
reviewed events type, severity and system-relatedness. AE were defined according to ISO14155-2003. 
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Study endpoints 
The primary objective of the study was to evaluate the safety of the TRIV configuration compared to standard CRT. 
Primary end point was the rate of severe adverse events (SAE). Secondary end points included type, rate, severity and 
timing of adverse events (AE), survival and proportion of patients with continuous CRT delivery, clinical composite score,  
NYHA class distribution in both groups, 6 minute walking distance, QOL scores, changes of echocardiographic indices of 
LV remodeling at 6 months. For the subset of patients followed-up at 12 months, they were considered as responders to 
CRT if they were alive, gained one NYHA class and had an absolute LVEF increase of more than 5 %, 10%, 15%. 
 
Statistics 
Data were analyzed on an intention-to-treat basis. All p values reported are nominal, and all statistical tests are 2-sided. 
P value < 0.05 was considered statistically significant. Data were expressed as mean ± SD, if continuous, and as 
absolute and relative frequency, if categorical. Comparisons between continuous distributions were performed by means 
of 2-sample Student t test or Wilcoxon test when distributions were not normal. Categorical distributions were compared 
by using the 2 test or the Fisher exact test for small samples. Multinomial logistic regression was used to estimate 
whether CCS and NYHA distributions were influenced by the tested treatment. Survival, time to first AE, time to first SAE 
and time to first device-related AE curves were determined by the Kaplan-Meier method. Time 0 was the date of 
enrolment and patients not experiencing an event were censored at 6 months FU visit date. Comparison of the 2 study 
groups was done using the log-rank test.  
 
Results 
First patient was enrolled in June 2009, and last patient FU was completed in January 2013; 76 patients were 
randomized (TRIV = 35, control = 41). There were no significant baseline differences between groups (Table I). The 
mean LVEF was 28.7 ± 6.3 % and the mean LV end-diastolic volume was 208 ± 74 ml. The mean intrinsic QRS and PR 
interval duration were 162 ± 21 and 194 ± 42 ms respectively (31% of patients with a PR interval > 200 ms). CRT-Ds 
were implanted in two third of the patients population (65.8 %). Implant was attempted for all but one patient assigned to 
standard CRT group who died before implant. A prophylactic antibiotic therapy was administered prior implant to 87.8% 
and 94.3% of the patients in the control and Triv Group. All of the patients were implanted successfully but one for which 
a second attempt with LV epicardial lead placement was required. Mean procedure duration was slightly longer in the 
TRIV group (118 ± 50 versus 98 ± 37 minutes in the control group, p=0,066). Mean X-ray exposure durations were 
similar: 17.0 ± 12.7 versus 18.4 ± 11.9 minutes (p=0,504). Lead electrical parameters measured individually were also 
comparable with the exception of the LV pacing threshold that was slightly lower in the TRIV group (1.48 ± 0.85 V vs 
1.12 ± 0.75 V at 0.5 ms). Loss of biventricular capture on the LV and septal RV leads connected with the Y-adaptor 
occurred at 1.47 ± 0.56 V at 0.5 ms (0.5 – 2.75 V). This latter value remained stable at pre-discharge: 1.47 ± 0.88 V. 
QRS durations decreased in both groups versus baseline : 144 ± 26.5 versus 136 ± 19.4 in control and TRIV group 
respectively (p=0.16). Of the 41 patients assigned to the control group, 3 did not complete six months FU — 2 died, and 
1 was explanted and not re-implanted. Of the 35 patients assigned to the TRIV group, 2 deceased and did not complete 
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six months of FU. No patient was lost to FU for the analysis of SAE. All patients continued to receive the assigned 
treatment for the intended duration of the study. Pacing thresholds remained acceptable throughout the entire study 
duration for most of the patients. TRIV pacing could be achieved for all of the patients with this pacing configuration 
however threshold was superior to 4.5 V / 0.4 ms for four of them. 
 
Primary end point 
At 6 month FU, there was no statistically significant difference between proportions of patients with at least one SAE in 
the control and TRIV groups (respectively 34.1% vs. 25.7%, p=0.425). Time to first SAE is presented in Figure 1. The 
probability of first SAE occurrence was similar in both groups (log rank test, p=0.52). In particular, device related 
infection rates were similar, with one infection in each group. 
 
Secondary end points: 
As for SAE, proportions of patients with at least one AE were similar in both groups (56.1 % in control versus 42.9% in 
TRIV group, p=0.25). This was also true for mortality (4.9% versus 5.7%). None of the reported deaths were procedure-
related; all were due to terminal heart failure. Time to first AE, to first system-related AE and to death were similar for 
both groups (log rank test, p=0.46, p=0.79, p=0.88 respectively).  
 
A majority of patients (81.6%) were free of any interruption of CRT delivery or occurrence of side effects. Proportion of 
patients with at least one system-related AE was equivalent in Control and TRIV group (19.5% and 17.1% respectively, 
p=0.79). 
 
Six-month CCS distributions were similar between control and TRIV group (p= 0.90) with a quite large proportion of 
responders to the therapy. Same observation was done for NYHA class distributions (p= 0.86) as well as for 6-minutes 
walking distance (p= 0.40) and QOL score (p = 0.2; Table II).  
At 6 month FU, there was no significant difference between the indices of LV remodeling observed in both groups: LVEF 
and LV dimensions improved in similar proportion (Table III).  
In the subset of patient followed-up at 12 months, there was no difference regarding proportion of patients with SAE 
(60% for controls versus 50% for TRIV patients). Compared to baseline, the improvement of the 6 minutes walking 
distance was not significant and was similar in both groups. QOL score improved significantly only in the TRIV group 
(p=0.03). LVEF and changes of LVEF was significantly superior in the TRIV group compared to the control group. Also 
the proportion of responders’ patients with LVEF gain of more than 5 %, 10 %, and 15 % was significantly superior in the 
TRIV group (Table IV). Finally there was a trend towards a greater proportion of patients with LVESV decrease of more 
than 15% and 25% in the TRIV group as compared to controls (85% versus 66%; 69% versus 47% respectively). 
 
Discussion 
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This is the first chronic prospective randomized study comparing conventional biventricular and TRIV pacing with the use 
of two RV leads.  
 
Feasibility: 
We demonstrated that implanting an additional RV lead for CRT is feasible and safe, and does not interfere with the 
proper device functioning including tachyarrhythmia management. Conversely to other multi –site pacing approaches 
using two LV leads, where procedure feasibility may be limited by the ability to successfully implant the second LV lead 
in a stable and appropriate position, our implant success rate was of 100%. Noteworthy, this was achieved without 
significantly prolonging procedure duration, highlighting the easiness of the implant technique. This was expected as the 
main driver for procedure duration is most of the time related to LV lead implantation. In published series on dual LV 
pacing, the implant success rate ranged from 85 to 100%8,9,10. In study by Lenarczyk et al., implantation of a second LV 
lead resulted in a 30 min prolongation of procedure duration associated with a significant increase in X-ray exposure10. 
 
In addition, TRIV was appropriately delivered throughout the entire FU duration. Although the Y connector enlarged the 
pocket size and limited the choice of LV lead pacing vectors, we did not observe a significant increase in device related 
AE. Of importance, as already mentioned by Lenarczyk, device related infection rate was low: only one was reported in 
each group. However, we cannot strongly conclude on this point as the design of our study did not allow capturing long-
term potential system-related infections. There is compelling evidence from long-term FU in large populations showing 
that infection risk increases with the number of leads and the number of re-operations. 
 
High ventricular thresholds were observed in only four patients in the TRIV group. This is likely related to the dissipation 
of part of the delivered pacing energy through the Y connector. A dedicated 4-channels device would definitely 
overcome these problems. In any case, the use of an additional pacing site will necessarily result in an increase of 
energy consumption which consequently will alter battery longevity. 
 
Increasing the number of implanted leads could promote vein thrombosis. Even though this was not systematically 
assessed, no clinical symptoms related to such an event were reported. 
 
Clinical impact: 
At 6 month FU, QoL, 6 min walking test and CCS evaluation significantly improved in both study groups. Conversely to 
what has been observed in TRIP HF study, we did not observe any additional clinical benefit provided by the TRIV 
pacing configuration at the time of FU. However, we did observe a significant improvement of LVEF and a trend towards 
a greater proportion of patients with LVESV decrease in the subset of patients followed up at 12 months. Proportion of 
responders was significantly higher in the TRIV group whatever the defined threshold value for LVEF changes (5%, 
10%, 15%). This reflects the fact that not only the long term response rate to CRT is higher but also the amplitude of 
response (super-responder rate) is much greater in the TRIV group as compared to the conventional group. It appears 
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that the additional benefit of TRIV configuration requires time to be detected as if the effect of TRIV lasted much longer 
than BIV on ventricular remodeling. This would explain by itself both the greater response rate and the greater LVEF 
improvement associated with TRIV.  
 
Some authors tested dual RV pacing alone. It appears to produce a beneficial clinical response in CRT candidates on an 
acute and long-term basis11. However, the remodeling effect of bifocal RV pacing is generally inferior to that of 
conventional biventricular pacing12. Several studies have been performed on the positioning of RV and LV pacing leads 
and their influence on the quality of resynchronization. Some authors compared septal versus apical positioning of the 
RV lead without demonstrating any difference in terms of clinical outcomes13. Others proposed to optimize RV lead 
positioning based on the echographic measurement of the aortic pre-ejection delay2 while others positioned the LV lead 
at the site of the latest mechanical activation14,15,16,17. Benefit of these approaches could be demonstrated through single 
centers studies. However, their implementation can be limited by constraints of the cardiac venous anatomy and may not 
be easy to reproduce at larger scale on a practical standpoint. Advanced echo measurements to detect sites of latest 
mechanical activation may be technically challenging14. 17. In addition their reproducibility remains arguable18. LV 
endocardial pacing looks promising19 even though it requires lifelong anti-coagulation treatment. A larger scale 
evaluation is now required to ensure procedure and long-term safety and evaluate more precisely clinical outcomes.  
 
It has been also proposed to reduce the number of pacing leads seeking for LV fusion. This pacing configuration, mainly 
dedicated to patients with LBBB, normal AV and RV conduction, could be an attractive option but its interest is not yet 
strongly demonstrated20.  
 
Last, several authors proposed to increase the number of pacing sites in order to improve CRT effectiveness. One of the 
reasons for the lack of response to conventional CRT may be the presence of functional or fixed lines of conduction 
block within the left ventricle and slow ventricular activation. This latter could be due to slow electrical interventricular 
conduction or abnormal electro-mechanical coupling. Multiplying the pacing points could potentially overcome all of 
these patho-physiological abnormalities and significantly shorten the global LV activation time. With the advent of 
quadripolar LV leads, initially proposed as a mean to avoid phrenic nerve stimulation, some preliminary data suggest 
that they could also provide hemodynamic benefit21. The latter could be related to the ability to pace from the basal or 
mid-LV region without compromising lead stability. Although the four poles are close together, it may also be related to 
the ability to simultaneously pace from all electrodes22. The impact on CRT efficiency remains to be proven chronically 
on large scale (MORE CRT MPP study; NCT02006069). A better mechanical resynchronization may be obtained using a 
third ventricular lead remotely positioned from the others. Several pacing configurations have been tested including 
either an additional LV or RV lead. A configuration with two LV leads was evaluated in two studies performed on de novo 
patients8,9 with promising results on the echographic and clinical parameters. We believe that the 2RV+1LV approach is 
not so different than the 1RV+2LV approach in terms of resynchronization effect. Provided that the pacing leads are 
positioned far enough one from each other, the paced areas would be close: a high septal RV lead would be near to a 
LV lead positioned in the great cardiac vein, while an apical RV lead would be near to a LV lead positioned in a 
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posterior/postero-lateral vein. According to electrical and anatomical characteristics, one approach rather than the other 
might suit better to a given patient.  
 
Study limitations 
The size of the population precludes drawing any definite conclusion on the clinical relevance of this technique. This was 
a pilot study designed to validate feasibility and build hypothesis for future studies. The pre-specified efficacy endpoints 
demonstrated no significant difference at 6 months while we observed a significant impact of TRIV pacing on a smaller 
sample at 12 months. Although it is possible that this technique may only convey modest incremental benefits, we still 
believe it is worth to perform a larger and longer term study to demonstrate its superiority. Echocardiographic evaluation 
was not performed in a core lab. All of the exams were done in a blinded fashion even though the sonographer may 
have visualized the leads. Most of the patients were enrolled in Rouen. However a potential center effect in the study 
results was ruled out. Also, only patients enrolled in Rouen were followed-up at one year. This implied lack of patient 
selection bias and only limited variations in echo measurements method in this subset of patients.  
 
Conclusion 
Our study supports TriV pacing as an effective and safe tool to improve patient clinical status. Larger studies are needed 
to assess the long term clinical benefit of this new pacing modality. 
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Legend figure 1 
____  BiV (conventional CRT) 
_ _ _  TriV 
X-axis: Month 
Y-axis: Proportion of patients free from severe adverse event 
 
Title figure 1 
Kaplan-Meier estimates of the time to first severe adverse event 
 
 
Clinical perspectives 
This is the first chronic prospective randomized study comparing conventional biventricular and triple site ventricular 
pacing with the use of two RV leads (TRIV). Our study supports TRIV as an effective and safe tool to improve patient 
clinical status. Development of new device technology is required to limit the drawbacks induced by the addition of a 
third lead and its impact on battery longevity (multi-port can). Although at mid-term follow-up, there was no significant 
difference between groups regarding clinical status, we observed an encouraging trend towards a better LV remodeling 
at 1-year in the TRIV group. The additional benefit of TRIV configuration may require time to be detected as if the effect 
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of TRIV pacing lasted much longer than BIV on ventricular remodeling. This would explain both the greater response 
rate and the greater LVEF improvement associated with TRIV we found in our study. A larger and longer term study is 
needed to demonstrate the potential superiority of this pacing technique over conventional CRT in order to be translated 
into daily clinical practice. 
 
 
All Control TRIV p 
n 76 41 35  
Age (year) 69.4 ± 10.7 69.9 ±  10.5 68.9 ± 11.2 0.71 
% male 71.1% 61% 82.9% 0.04 
Ischemic heart disease (%) 43.4% 43.9% 42.9% 0.93 
Paroxysmal AF (%)  26.3% 26.8% 25.7% 0.91 
QRS duration (ms) 162 ± 21 160 ± 21 164 ± 21 0.20 
CRT-D proportion (%) 65.8% 63.4% 68.6% 0.64 
NYHA class  
% II  
% III 
% IV   
6.6% 
85.5% 
7.9% 
12.2% 
80.5% 
7.3% 
0% 
91.4% 
8.6% 
0.09 
LVEF (%) 28.7 ± 6.3% 29.6 ± 6.3 % 27.7 ± 6.4 % 0.12 
LV end of diastole volume (ml) 202 ± 70.7 208 ± 73.8 195 ± 67.5 0.55 
LV end of systole volume (ml) 145 ± 58.9 147 ± 61.8 144 ± 56.4 0.96 
LV end of diastole diameter (mm) 66.7 ± 9.76 66.9 ± 10,5 66.5 ± 8.99 0.86 
LV end of systole diameter (mm) 57.4 ± 11.5    58.6 ± 11.6 55.9 ± 11.4 0.31 
6 minute walking distance (m) / n  309 ± 111 / 66 304 ± 98 / 36 315 ± 125 / 30 0.68 
QOL score 37.2 ± 18.1 36.5 ± 19.8 38.0 ± 16.2 0.73 

Table I: Population characteristics at baseline  

 
Baseline 6 month FU 
 
n Control n TRIV p n Control n TRIV p 
Clinical composite score: 
% Improved  
% Unchanged  
% Worsened 
 
38 
81.6% 
13.2% 
5.2% 
33 
78.8% 
18.2% 
3.0% 
0.90 
NYHA class: 
% I  
% II 
% III 
% IV 
41 
 
0% 
12.2% 
80.5% 
7.3% 
35 
 
0% 
0% 
91.4% 
8.6% 
0.09 38 
 
21.1% 
55.3% 
23.7% 
0% 
33 
 
18.2% 
63.6% 
18.2% 
0% 
0.86 
6 min. walking distance (m) 36 304 ± 98 30 315 ± 125 0.68 33 377 ± 97 32 355 ± 117 0.40 
QOL Score  41 38.0 ± 16.2 35 37.2 ± 18.1 0.73 36 29.6 ± 23.2 33 22.2 ± 16.1 0.27 
 
Table II: Functional status at baseline and 6 month FU  
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Baseline 6 Month FU 
 
n Control n TRIV p n Control n TRIV p 
LVEF (%) 41 29.6 ± 6.3  35 27.7 ± 6.4 % 0.12 36 39.7 ± 11.2 32 41.9 ± 11.1 0.43 
LV end of diastole volume (ml) 39 208 ± 73.8 35 195 ± 67.5 0.55 31 159 ± 66.2 31 160 ± 71.2 0.95 
LV end of systole volume (ml) 38 147 ± 61.8 35 144 ± 56.4 0.96 30 95.9 ± 57.8 31 104 ± 60.5 0.71 
LV end of diastole diameter 
(mm) 41 66.9 ± 10,5 35 66.5 ± 8.99 0.86 34 61.1 ± 10.2 32 60.2 ± 9.8 0.72 
LV end of systole diameter 
(mm) 41 58.6 ± 11.6 34 55.9 ± 11.4 0.31 32 50.9 ± 12.7 30 50.0 ± 10.4 0.76 
 
Table III: Echocardiographic parameters at baseline and 6 month FU 
 
 
Control (n=20) TRIV (n=20) p* 
 Baseline 12M - FU p Baseline 12M - FU p 
LVEF (%) 26.8 ± 6.6 35.1 ± 11 <0.01 26.4 ± 5.3 44.5 ± 11 <0.001 0.01 
Responders rate with LVEF gain > 5 % 40% 70% 0.05 
Responders rate with LVEF gain > 10 % 25% 60% 0.02 
Responders rate with LVEF gain > 15 % 15% 45% 0.03 
LV end of systole volume (ml) 155 ± 60 119 ± 68 <0.01 163 ± 57 100 ± 59 <0.001 0.35 
Proportion with LVESV decrease > 15% 66% 85% 0.25 
Proportion with LVESV decrease > 25% 47% 69% 0.21 
LV end of diastole volume (ml) 210 ± 65 176 ± 80 <0.05 222 ± 71 171 ± 82 <0.01 0.85 
LV end of diastole diameter (mm) 71 ± 11 66 ± 12 <0.05 71 ± 7 63 ± 11 <0.01 0.41 
LV end of systole diameter (mm) 61 ± 12 54 ± 15 <0.05 60 ± 7 47 ± 12 <0.001 0.11 
Left pre-ejection interval (ms) 151 ± 30 134 ± 27 NS 147 ± 25 126 ± 23 0.08 0.32 
Inter-ventricular delay (ms) 46 ± 30 22 ± 13 <0.05 37 ± 26 23 ± 13 0.05 0.81 
LV filling time (% RR) 45 ± 10 45 ± 8 NS 44 ± 9 47 ± 13 NS 0.56 
NYHA Class I/II/III/IV (n) 0/2/16/2 4/9/5/0  0/0/19/1 8/7/1/0   
6-minutes walking distance (m) 300 ± 108 376 ± 106 0.27 363 ± 119 446 ± 87 0.15 0.04 
QOL Score 43 ± 21 32 ± 26 0.16 36 ± 16 24 ± 18 0.03 0.3 
*BiV vs TriV at 12–month FU 
 
Table IV: Patient characteristics at baseline and 12 month FU in the subset of patients enrolled in Rouen 
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